Were economic evaluations well reported for the newly listed oncology drugs in China's national reimbursement drug list.

ABSTRACT:

Purpose

To assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China's 2020 National Reimbursement Drug List (NRDL).

Methods

A comprehensive search was conducted to identify economic evaluation studies of negotiated oncology drugs listed in China's 2020 NRDL using the PubMed/MEDLINE, Embase, Web of Science, CNKI, SinoMed, and WanFang Database up to March 31, 2021. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist scored the reporting quality between 0 and 100. A linear regression analysis was employed to examine the influence of various characteristics on the reporting quality scores.

Results

Eighty papers were included in the study, with the majority published during the past deca

SUBMITTER: Liu L 

PROVIDER: S-EPMC9719239 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature